VOYAGER THERAPEUTICS INC's ticker is VYGR and the CUSIP is 92915B106. A total of 51 filers reported holding VOYAGER THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $575,671 | -28.8% | 74,280 | +5.2% | 0.00% | – |
Q2 2023 | $808,596 | -25.0% | 70,620 | -49.5% | 0.00% | – |
Q1 2023 | $1,078,228 | +152.8% | 139,848 | +100.0% | 0.00% | – |
Q4 2022 | $426,469 | +3.0% | 69,913 | +0.0% | 0.00% | – |
Q3 2022 | $414,000 | 0.0% | 69,902 | -0.1% | 0.00% | – |
Q2 2022 | $414,000 | -37.2% | 70,002 | -19.0% | 0.00% | – |
Q1 2022 | $659,000 | +21866.7% | 86,427 | +7293.2% | 0.00% | – |
Q3 2021 | $3,000 | -25.0% | 1,169 | +25.6% | 0.00% | – |
Q2 2021 | $4,000 | +100.0% | 931 | +86.2% | 0.00% | – |
Q1 2021 | $2,000 | -99.4% | 500 | -99.0% | 0.00% | – |
Q4 2020 | $346,000 | -46.5% | 48,429 | -20.1% | 0.00% | – |
Q3 2020 | $647,000 | -77.7% | 60,629 | -73.6% | 0.00% | – |
Q2 2020 | $2,899,000 | +37.9% | 229,729 | 0.0% | 0.00% | – |
Q1 2020 | $2,102,000 | -34.4% | 229,729 | 0.0% | 0.00% | – |
Q4 2019 | $3,205,000 | -52.6% | 229,729 | -41.6% | 0.00% | -100.0% |
Q3 2019 | $6,766,000 | -53.3% | 393,129 | -26.1% | 0.00% | -50.0% |
Q2 2019 | $14,485,000 | +2.6% | 532,129 | -27.9% | 0.00% | 0.0% |
Q1 2019 | $14,117,000 | +64.8% | 737,562 | -19.0% | 0.00% | +100.0% |
Q4 2018 | $8,564,000 | -67.2% | 911,062 | -34.0% | 0.00% | -66.7% |
Q3 2018 | $26,105,000 | -42.7% | 1,379,762 | -40.8% | 0.00% | -40.0% |
Q2 2018 | $45,572,000 | -15.6% | 2,332,221 | -18.9% | 0.01% | -16.7% |
Q1 2018 | $54,002,000 | -1.0% | 2,873,992 | -12.6% | 0.01% | 0.0% |
Q4 2017 | $54,565,000 | -28.3% | 3,287,051 | -11.1% | 0.01% | -33.3% |
Q3 2017 | $76,143,000 | +125.9% | 3,698,051 | -1.7% | 0.01% | +125.0% |
Q2 2017 | $33,708,000 | -32.3% | 3,762,051 | 0.0% | 0.00% | -33.3% |
Q1 2017 | $49,810,000 | -1.6% | 3,762,051 | -5.3% | 0.01% | -14.3% |
Q4 2016 | $50,627,000 | +6.1% | 3,973,851 | 0.0% | 0.01% | +16.7% |
Q3 2016 | $47,726,000 | +9.3% | 3,973,851 | 0.0% | 0.01% | 0.0% |
Q2 2016 | $43,673,000 | +28.2% | 3,973,851 | +1.8% | 0.01% | +20.0% |
Q1 2016 | $34,067,000 | -60.1% | 3,902,348 | 0.0% | 0.01% | -54.5% |
Q4 2015 | $85,462,000 | – | 3,902,348 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP III, LLC | 6,391,176 | $60,077,000 | 50.34% |
ARMISTICE CAPITAL, LLC | 2,836,000 | $26,658,000 | 2.02% |
Casdin Capital, LLC | 1,128,075 | $10,604,000 | 1.81% |
BB BIOTECH AG | 2,865,841 | $26,939,000 | 0.86% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 1,284,697 | $12,076,000 | 0.81% |
Aevitas Wealth Management, Inc. | 48,300 | $454,000 | 0.46% |
GREAT POINT PARTNERS LLC | 365,132 | $3,432,000 | 0.43% |
Patriot Financial Group Insurance Agency, LLC | 61,320 | $576,000 | 0.38% |
HARBOURVEST PARTNERS LLC | 72,726 | $684,000 | 0.32% |
Birchview Capital, LP | 33,000 | $310,000 | 0.29% |